Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older

NCT01242670 is registered in ClinicalTrials.gov with Alachua Government Services, Inc. as lead sponsor.

NCT NCT01242670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older
Lead sponsor
Alachua Government Services, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2011
Completion date
October 31, 2012
Enrollment
1,968 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

prophylaxis of ross river virus infection